Baird Says Time is Right to Own NewLink Genetics (NLNK)

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

Baird reiterated an Outperform rating on NewLink Genetics (NASDAQ: NLNK) and raised its price target to $20.00 (from $17.00).

"Though the quarterly print was uneventful, we continue to like NLNK for its significant pipeline potential, with first HyperAcute Pancreas Phase III interim look in early-2013 – an event that we think brings real un-modeled upside potential as our base case assumes a 2015 approval," said analyst Christopher J. Raymond.

He thinks the stock recent 15 percent pullback offers a compelling entry point in front of the pivotal HyperAcute data next year.

For an analyst ratings summary and ratings history on NewLink Genetics click here. For more ratings news on NewLink Genetics click here.

Shares of NewLink Genetics closed at $13.81 yesterday, with a 52 week range of $6.25-$18.00.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Dollar Tree (DLTR) Beats But Looks Stretched - Jefferies
• Toll Bros. (TOL) Estimates/PT Raised at Compass Point
• Williams-Sonoma (WSM) Delivers 'Clean' Q1 Beat - Analyst

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Robert W Baird

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?